6.
Darwich A, Polasek T, Aronson J, Ogungbenro K, Wright D, Achour B
. Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. Annu Rev Pharmacol Toxicol. 2020; 61:225-245.
DOI: 10.1146/annurev-pharmtox-033020-113257.
View
7.
Polasek T, Tucker G, Sorich M, Wiese M, Mohan T, Rostami-Hodjegan A
. Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. Br J Clin Pharmacol. 2017; 84(3):462-476.
PMC: 5809347.
DOI: 10.1111/bcp.13480.
View
8.
Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A
. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009; 5(2):211-23.
DOI: 10.1517/17425250802691074.
View
9.
Polasek T, Patel F, Jensen B, Sorich M, Wiese M, Doogue M
. Predicted metabolic drug clearance with increasing adult age. Br J Clin Pharmacol. 2012; 75(4):1019-28.
PMC: 3612720.
DOI: 10.1111/j.1365-2125.2012.04446.x.
View
10.
Kosari S, Yee K, Mulhall S, Thomas J, Jackson S, Peterson G
. Pharmacists' Perspectives on the Use of My Health Record. Pharmacy (Basel). 2020; 8(4).
PMC: 7712990.
DOI: 10.3390/pharmacy8040190.
View
11.
Polasek T, Ambler K, Scott H, Sorich M, Kaub P, Rowland A
. Targeted pharmacotherapy after somatic cancer mutation screening. F1000Res. 2017; 5:1551.
PMC: 5247780.
DOI: 10.12688/f1000research.9040.2.
View
12.
Polasek T, Shakib S, Rostami-Hodjegan A
. Precision medicine technology hype or reality? The example of computer-guided dosing. F1000Res. 2019; 8:1709.
PMC: 6852323.
DOI: 10.12688/f1000research.20489.1.
View
13.
Mostafa S, Polasek T, Bousman C, Mueller D, Sheffield L, Rembach J
. Pharmacogenomics in psychiatry - the challenge of cytochrome P450 enzyme phenoconversion and solutions to assist precision dosing. Pharmacogenomics. 2022; 23(15):857-867.
DOI: 10.2217/pgs-2022-0104.
View
14.
Kloypan C, Koomdee N, Satapornpong P, Tempark T, Biswas M, Sukasem C
. A Comprehensive Review of and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine. Pharmaceuticals (Basel). 2021; 14(11).
PMC: 8622011.
DOI: 10.3390/ph14111077.
View
15.
Bruci A, Tuccinardi D, Tozzi R, Balena A, Santucci S, Frontani R
. Very Low-Calorie Ketogenic Diet: A Safe and Effective Tool for Weight Loss in Patients With Obesity and Mild Kidney Failure. Nutrients. 2020; 12(2).
PMC: 7071259.
DOI: 10.3390/nu12020333.
View
16.
Dieleman J, Squires E, Bui A, Campbell M, Chapin A, Hamavid H
. Factors Associated With Increases in US Health Care Spending, 1996-2013. JAMA. 2017; 318(17):1668-1678.
PMC: 5818797.
DOI: 10.1001/jama.2017.15927.
View
17.
Montastruc J, Benevent J, Montastruc F, Bagheri H, Despas F, Lapeyre-Mestre M
. What is pharmacoepidemiology? Definition, methods, interest and clinical applications. Therapie. 2018; 74(2):169-174.
DOI: 10.1016/j.therap.2018.08.001.
View
18.
Polasek T
. Calculation of the pharmacogenomics benefit score for patients with medication-related problems. Front Genet. 2023; 14:1152585.
PMC: 10196203.
DOI: 10.3389/fgene.2023.1152585.
View
19.
Rowland A, van Dyk M, Hopkins A, Mounzer R, Polasek T, Rostami-Hodjegan A
. Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure. Clin Pharmacol Ther. 2018; 104(6):1219-1228.
DOI: 10.1002/cpt.1076.
View
20.
Angehrn Z, Haldna L, Zandvliet A, Berglund E, Zeeuw J, Amzal B
. Artificial Intelligence and Machine Learning Applied at the Point of Care. Front Pharmacol. 2020; 11:759.
PMC: 7314939.
DOI: 10.3389/fphar.2020.00759.
View